Alosaimy Sara, Molina Kyle C, Claeys Kimberly C, Andrade Justin, Truong James, King Madeline A, Pullinger Benjamin M, Huang Glen, Morrisette Taylor, Lagnf Abdalhamid M, Davis Susan L, Rybak Michael J
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit ,Michigan, USA.
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Open Forum Infect Dis. 2020 Mar 2;7(5):ofaa071. doi: 10.1093/ofid/ofaa071. eCollection 2020 May.
Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.
依拉环素（ERV）用于35例患有各种感染的患者。最常见的病原体是[此处原文缺失相关内容]，30天生存率为74%。30天无复发以及感染体征和症状消退的比例分别为91%和57%。依拉环素耐受性良好，仅有1例患者因不良事件导致停药。
